---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-011486"
form_type: "8-K"
ticker: "DWTX"
cik: "0001818844"
company_name: "Dogwood Therapeutics, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:09:58.777493+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Virios Q2 net loss $1.0M; Long-COVID Phase 2a data expected Oct 2024

## Summary
- Net loss $1.0M ($0.05/sh) vs $1.4M ($0.08/sh) in Q2 2023; revenue was $0.
- Cash $3.0M at June 30, 2024; expects runway into Q1 2025 after $1.7M public offering.
- Enrollment completed in Long-COVID Phase 2a (valacyclovir/celecoxib vs placebo); top-line data October 2024.
- R&D expense fell to $0.3M from $0.6M; G&A fell to $0.7M from $0.9M, both YoY.
- Blinded safety analysis shows no serious adverse events; study drug well tolerated to date.

## SEC filing metadata
- accession: 0001558370-24-011486
- form_type: 8-K
- ticker: DWTX
- cik: 0001818844
- company_name: Dogwood Therapeutics, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/0001558370-24-011486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818844/000155837024011486/viri-20240808x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-011486
- JSON: https://secwatch.observer/filing/0001558370-24-011486.json
- Plain text: https://secwatch.observer/filing/0001558370-24-011486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.